Aclaris Therapeutics, Inc. (ACRS)
USD 1.27
(6.3%)
USD 1.27
(6.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 40.22 Million USD | -29.4% |
| 2022 | 56.97 Million USD | 5.76% |
| 2021 | 53.87 Million USD | 62.58% |
| 2020 | 33.13 Million USD | 16.73% |
| 2019 | 28.38 Million USD | -53.04% |
| 2018 | 60.44 Million USD | 231.24% |
| 2017 | 18.24 Million USD | 176.68% |
| 2016 | 6.59 Million USD | 324.12% |
| 2015 | 1.55 Million USD | -95.92% |
| 2014 | 38.13 Million USD | 63.17% |
| 2013 | 23.37 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 32.05 Million USD | -20.32% |
| 2024 Q2 | 27.24 Million USD | -14.98% |
| 2023 Q3 | 62.02 Million USD | 10.95% |
| 2023 Q4 | 40.22 Million USD | -35.14% |
| 2023 Q1 | 52.89 Million USD | -7.16% |
| 2023 Q2 | 55.89 Million USD | 5.68% |
| 2023 FY | 40.22 Million USD | -29.4% |
| 2022 Q1 | 46.32 Million USD | -14.0% |
| 2022 FY | 56.97 Million USD | 5.76% |
| 2022 Q4 | 56.97 Million USD | 19.21% |
| 2022 Q3 | 47.79 Million USD | 13.19% |
| 2022 Q2 | 42.22 Million USD | -8.86% |
| 2021 Q4 | 53.87 Million USD | 14.83% |
| 2021 Q1 | 49.1 Million USD | 48.2% |
| 2021 Q2 | 54.23 Million USD | 10.44% |
| 2021 FY | 53.87 Million USD | 62.58% |
| 2021 Q3 | 46.91 Million USD | -13.49% |
| 2020 Q4 | 33.13 Million USD | 6.39% |
| 2020 FY | 33.13 Million USD | 16.73% |
| 2020 Q3 | 31.14 Million USD | -12.6% |
| 2020 Q2 | 35.63 Million USD | -7.77% |
| 2020 Q1 | 38.63 Million USD | 36.12% |
| 2019 Q3 | 75.14 Million USD | -6.08% |
| 2019 Q2 | 80 Million USD | 12.8% |
| 2019 Q1 | 70.93 Million USD | 17.35% |
| 2019 FY | 28.38 Million USD | -53.04% |
| 2019 Q4 | 28.38 Million USD | -62.22% |
| 2018 Q3 | 29.84 Million USD | 8.08% |
| 2018 Q2 | 27.61 Million USD | 37.05% |
| 2018 Q1 | 20.15 Million USD | 10.43% |
| 2018 FY | 60.44 Million USD | 231.24% |
| 2018 Q4 | 60.44 Million USD | 102.5% |
| 2017 FY | 18.24 Million USD | 176.68% |
| 2017 Q1 | 5.92 Million USD | -10.22% |
| 2017 Q4 | 18.24 Million USD | 6.51% |
| 2017 Q3 | 17.13 Million USD | 97.74% |
| 2017 Q2 | 8.66 Million USD | 46.33% |
| 2016 Q3 | 4.94 Million USD | -15.43% |
| 2016 Q4 | 6.59 Million USD | 33.26% |
| 2016 FY | 6.59 Million USD | 324.12% |
| 2016 Q2 | 5.85 Million USD | 44.17% |
| 2016 Q1 | 4.05 Million USD | 161.03% |
| 2015 Q2 | 1.42 Million USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q3 | 80.2 Million USD | 5520.53% |
| 2015 FY | 1.55 Million USD | -95.92% |
| 2015 Q4 | 1.55 Million USD | -98.06% |
| 2014 FY | 38.13 Million USD | 63.17% |
| 2014 Q4 | 38.13 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 23.37 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Applied DNA Sciences, Inc. | 8.77 Million USD | -358.198% |
| Aspira Women's Health Inc. | 8.62 Million USD | -366.28% |
| Biodesix, Inc. | 94.51 Million USD | 57.44% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -2209.263% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -1094.963% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -1094.963% |
| Bionano Genomics, Inc. | 118.24 Million USD | 65.981% |
| CareDx, Inc | 223.28 Million USD | 81.985% |
| Check-Cap Ltd. | 1.33 Million USD | -2924.511% |
| Castle Biosciences, Inc. | 86.54 Million USD | 53.519% |
| DarioHealth Corp. | 38.24 Million USD | -5.18% |
| Exact Sciences Corporation | 3.32 Billion USD | 98.791% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 71.231% |
| Guardant Health, Inc. | 1.62 Billion USD | 97.529% |
| ICON Public Limited Company | 7.74 Billion USD | 99.481% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 97.734% |
| Illumina, Inc. | 4.36 Billion USD | 99.079% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -618.877% |
| iSpecimen Inc. | 6.07 Million USD | -561.823% |
| Standard BioTools Inc. | 159.86 Million USD | 74.838% |
| MDxHealth SA | 121.92 Million USD | 67.007% |
| 23andMe Holding Co. | 206.64 Million USD | 80.534% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 96.336% |
| Myriad Genetics, Inc. | 312.9 Million USD | 87.144% |
| Mainz Biomed B.V. | 12.15 Million USD | -230.811% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -3573.081% |
| NeoGenomics, Inc. | 739.69 Million USD | 94.562% |
| Neogen Corporation | 1.44 Billion USD | 97.207% |
| Inotiv, Inc. | 588.04 Million USD | 93.159% |
| Natera, Inc. | 691.79 Million USD | 94.185% |
| OpGen, Inc. | 13.44 Million USD | -199.215% |
| OPKO Health, Inc. | 622.47 Million USD | 93.538% |
| Psychemedics Corporation | 6.59 Million USD | -509.67% |
| Prenetics Global Limited | 44.01 Million USD | 8.605% |
| Prenetics Global Limited | 44.01 Million USD | 8.605% |
| Precipio, Inc. | 3.67 Million USD | -995.479% |
| Personalis, Inc. | 95.65 Million USD | 57.948% |
| RadNet, Inc. | 2.07 Billion USD | 98.06% |
| Sera Prognostics, Inc. | 25.28 Million USD | -59.103% |
| Sotera Health Company | 2.68 Billion USD | 98.503% |
| Neuronetics, Inc. | 81.64 Million USD | 50.728% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -85.587% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -85.587% |
| Trinity Biotech plc | 83.38 Million USD | 51.758% |
| T2 Biosystems, Inc. | 62.83 Million USD | 35.98% |
| Twist Bioscience Corporation | 152.97 Million USD | 73.704% |
| Exagen Inc. | 34.25 Million USD | -17.448% |